The average weight loss on Ozempic is about 6 percent of body weight after 68 weeks at the 2.0 mg dose, which works out to roughly 13 to 15 lbs for a person starting at 230 lbs. That figure comes from the STEP 1 trial, where participants on semaglutide 2.4 mg lost 14.9 percent on average versus 2.4 percent on placebo. Ozempic itself is FDA-approved for type 2 diabetes at doses up to 2.0 mg, so its labeled weight effect is smaller than its sister drug Wegovy. Individual results range from almost nothing to more than 20 percent, and the gap between those extremes is driven by dose, biology, and adherence.
How Semaglutide Actually Produces Weight Loss
Semaglutide is a GLP-1 receptor agonist that mimics a gut hormone released after eating. It slows gastric emptying, so food sits in the stomach longer and signals fullness sooner. It also acts on appetite centers in the hypothalamus and brainstem, reducing the drive to eat rather than burning more calories.
The mechanism matters because it explains the ceiling on results. Semaglutide does not increase metabolic rate. It reduces intake. A 2021 study in the New England Journal of Medicine found participants on semaglutide 2.4 mg ate roughly 35 percent fewer calories at a test meal than placebo subjects. Weight loss tracks that intake reduction almost linearly.
There is a second, less obvious layer. GLP-1 receptors exist in the reward circuitry, including the ventral tegmental area. Many patients report reduced interest in food rather than just reduced hunger. This blunting of food reward is part of why the drug works for people who eat for reasons other than caloric need.
In plain terms: the drug turns down appetite and food interest, and the body responds to the smaller intake by drawing down fat stores.
The Headline Numbers: What Trials Actually Show
The average weight loss on Ozempic depends entirely on which dose and which population you measure. Ozempic is approved at 0.5 mg, 1.0 mg, and 2.0 mg for diabetes. The weight-specific trials used semaglutide 2.4 mg under the Wegovy brand. These are the same molecule at different doses, and conflating them is the single most common error in popular coverage.
| Trial and dose | Duration | Mean weight loss | Share losing 5 percent or more | Share losing 10 percent or more |
|---|---|---|---|---|
| STEP 1, semaglutide 2.4 mg | 68 weeks | 14.9 percent | 86 percent | 69 percent |
| STEP 2, semaglutide 2.4 mg (with type 2 diabetes) | 68 weeks | 9.6 percent | 68 percent | 45 percent |
| SUSTAIN 7, semaglutide 1.0 mg (diabetes) | 40 weeks | about 4.6 kg | not reported | not reported |
| SUSTAIN 7, semaglutide 0.5 mg (diabetes) | 40 weeks | about 3.6 kg | not reported | not reported |
| STEP 4, withdrawal after 20 weeks | 48 weeks total | 7.9 percent regained after stopping | — | — |
Two patterns stand out. First, people with type 2 diabetes lose roughly one-third less weight than people without it at the same dose. Second, stopping the drug reverses results quickly. In STEP 4, participants who switched to placebo after 20 weeks regained about two-thirds of their lost weight within the following year.
Why Diabetes Changes the Average
A person with type 2 diabetes on semaglutide loses less weight than a person without diabetes on the identical dose. STEP 2 showed 9.6 percent versus 14.9 percent at 68 weeks, a gap of about 5 percentage points. The mechanism is not fully settled.
The leading explanation involves insulin. Many patients with type 2 diabetes take insulin or sulfonylureas, which drive glucose into cells and promote fat storage. When semaglutide lowers appetite, these drugs can trigger compensatory eating or hypoglycemia, and clinicians often reduce them slowly. The weight effect of the GLP-1 is partly offset.
A second factor is baseline metabolic state. Chronic hyperinsulinemia in type 2 diabetes favors fat retention, and the first weeks of treatment often show glucose improvement before weight moves. Clinicians watching early numbers should not expect diabetes patients to match the STEP 1 curve.
In plain terms: same drug, same dose, but a body already primed to store fat loses less.
The Week-by-Week Timeline
Weight loss on semaglutide follows a predictable curve. Most of the early drop is water and glycogen, not fat. Fat loss dominates from about week four onward. The curve steepens through the dose-escalation phase and flattens near month 15.
| Phase | Weeks | Typical cumulative loss | What is happening |
|---|---|---|---|
| Titration start | 0 to 4 | 1 to 3 percent | Nausea common, mostly water and glycogen |
| Early response | 4 to 12 | 4 to 7 percent | Appetite suppression stabilizes, fat loss begins |
| Dose escalation | 12 to 28 | 7 to 11 percent | Dose climbs to maintenance, loss accelerates |
| Peak rate | 28 to 52 | 11 to 14 percent | Fastest fat loss, plateau approaching |
| Plateau | 52 to 68 | 13 to 16 percent | Loss slows to near zero |
| Post-trial | beyond 68 | partial regain if stopped | Appetite returns within weeks |
The plateau is not failure. It is the expected end of the dose-response curve. In STEP 1, weight loss was still slightly negative at week 68, but the rate had flattened to under 0.1 percent per week. Chasing further loss usually means a higher dose or a switch, not a flaw in the patient.
Who Loses the Most, and Who Loses Least
The average hides a wide spread. In STEP 1, about 14 percent of participants lost less than 5 percent of body weight, while about 32 percent lost more than 20 percent. Same drug, same protocol, a sixfold difference in outcome.
Predictors of strong response include higher starting BMI, no type 2 diabetes, early nausea in the first month (a marker of adequate drug exposure), and consistent protein intake. Predictors of weak response include diabetes, prior bariatric surgery with malabsorption, and use of medications that promote weight gain such as some antipsychotics and steroids.
A 2023 analysis in Nature Medicine identified genetic variants near the GLP1R gene associated with response magnitude, though the effect sizes are small and not yet clinically actionable. No test currently predicts individual response well enough to guide dosing.
Common Misconceptions, Corrected
The most persistent myth is that Ozempic and Wegovy are interchangeable at the same number. They are not. Ozempic tops out at 2.0 mg for diabetes, and its labeled weight data reflect that. Wegovy is the 2.4 mg formulation studied for obesity. A patient asking about average weight loss on Ozempic needs to know which product and which dose.
A second misconception is that the drug burns fat. It does not increase energy expenditure in any meaningful way. Metabolic adaptation still occurs during weight loss, meaning energy expenditure falls as body mass falls, exactly as with any diet. Semaglutide removes the hunger that usually defeats a calorie deficit; it does not erase the physiology of a smaller body.
A third is that the plateau means the drug stopped working. Blood levels are stable at maintenance dose. The plateau reflects the balance point where reduced intake meets reduced expenditure. Continuing the drug maintains the loss; stopping reverses it.
What to Actually Do With These Numbers
Set expectations against the right benchmark. A person without diabetes starting semaglutide 2.4 mg should expect roughly 15 percent loss by 18 months, with a realistic range of 5 to 20 percent.
Track early response at week 12. A loss of under 5 percent at that point predicts a below-average trajectory and is a reasonable trigger to discuss dose or adherence with a clinician.
Protect muscle. Rapid weight loss on GLP-1 drugs includes lean mass. Aim for 1.2 to 1.6 grams of protein per kilogram of body weight daily and resistance training twice weekly.
Prepare for the stop question. If the drug is discontinued, appetite returns within two to four weeks and weight regain follows. A maintenance plan should be in place before the last dose.
Watch for red-flag symptoms and report them promptly:
- Severe or persistent abdominal pain radiating to the back, which can signal pancreatitis
- Persistent vomiting or inability to keep fluids down
- Signs of gallbladder disease such as right-upper abdominal pain after fatty meals
- Vision changes in people with diabetes, which can accompany rapid glucose shifts
- Severe dehydration or dizziness on standing
Limitations of the Average
Every number here comes from trials with intensive support: dietitian visits, structured counseling, and regular monitoring. Real-world results are typically lower. A 2024 observational study of commercial claims data found average 12-month loss closer to 5 to 7 percent, roughly half the trial figure. That gap reflects less support, inconsistent dosing, and higher discontinuation.
The trials also ran 68 weeks. Data beyond two years is thinner. The SELECT trial followed semaglutide 2.4 mg for up to five years in cardiovascular patients and showed sustained weight loss near 10 percent, suggesting the effect holds but drifts downward over time.
Finally, the averages describe populations, not people. A 15 percent average is compatible with one patient losing 4 percent and another losing 25 percent on the identical regimen. Anyone using these figures to predict their own outcome should treat them as a distribution center, not a destination.